{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:40:12Z","timestamp":1790973612855,"version":"4.1.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,20]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Detection of light chain (LC) monoclonal gammopathies (MGs) traditionally relies on serum free LC (FLC) \u03ba, \u03bb, and their ratio (\u03ba\/\u03bb) reference ranges based on a mostly White population. We investigated FLC values in a racially diverse population by screening 10\u2009035 individuals for heavy chain MG, identifying 9028 negative cases whose FLC were measured. Participants included 4149 from the PROMISE study (United States, n\u00a0=\u00a02383; South Africa, n\u00a0=\u00a01766) and 4879 from the Mass General Brigham Biobank, with 44% self-identifying as Black. Using standard FLC reference ranges, 1074 of 10\u2009035 individuals (10.7%) were diagnosed with LC monoclonal gammopathy of undetermined significance (MGUS), with 99% being \u03ba-restricted. In the United States, 14.8% of Black and 4% of White individuals were diagnosed (P\u00a0&amp;lt; .01). Among US participants of African (AFR) and European (EUR) genetic ancestry, 14.4% AFR and 2.9% EUR were diagnosed (P\u00a0&amp;lt; .01). Among South Africans (100% Black), 27.8% were diagnosed using standard ranges. To avoid overdiagnosis, we propose a new \u03ba\/\u03bb ratio reference range (0.686 to 2.10) for populations of AFR descent with normal renal function, with standard values for \u03ba and \u03bb being 7.97 to 77.50 mg\/L and 6.20 to 49.20 mg\/L, respectively. This reduces LC-MGUS overdiagnosis by 91% (10.7% vs 0.97%). Using the new reference, LC-MGUS accounts for 8.8% of MGUS cases, with 74% being \u03ba-restricted, consistent with LC myeloma rates. These findings highlight the importance of basing disease definitions, such as MGUS, on diverse populations. Adopting our proposed FLC reference values would reduce MGUS overdiagnosis among Black individuals, avoiding unnecessary financial, psychological, and medical consequences. This study includes data from NCT03689595.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024026078","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T21:34:07Z","timestamp":1732224847000},"page":"840-849","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Serum free light chains in a racially diverse population including African Americans and populations from South Africa"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3722-9696","authenticated-orcid":false,"given":"Luca","family":"Bertamini","sequence":"first","affiliation":[{"name":"1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-7294","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Alberge","sequence":"additional","affiliation":[{"name":"1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"3Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Lee","sequence":"additional","affiliation":[{"name":"1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"3Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"},{"name":"4Department of Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4023-6566","authenticated-orcid":false,"given":"Habib","family":"El-Khoury","sequence":"additional","affiliation":[{"name":"1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4815-0799","authenticated-orcid":false,"given":"Sungjae","family":"Kim","sequence":"additional","affiliation":[{"name":"1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Fleming","sequence":"additional","affiliation":[{"name":"1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"Murphy","sequence":"additional","affiliation":[{"name":"1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6268-7038","authenticated-orcid":false,"given":"Julia","family":"Colchie","sequence":"additional","affiliation":[{"name":"1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya I.","family":"Davis","sequence":"additional","affiliation":[{"name":"1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Perry","sequence":"additional","affiliation":[{"name":"1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Lightbody","sequence":"additional","affiliation":[{"name":"1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"3Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Allam","sequence":"additional","affiliation":[{"name":"1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"3Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindokuhle N.","family":"Goqwana","sequence":"additional","affiliation":[{"name":"5Division of Internal Medicine, Faculty of Health Sciences, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa"},{"name":"6Clinical Haematology Unit, Department of Medicine, Faculty of Health Sciences, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5503-9291","authenticated-orcid":false,"given":"Vinitha","family":"Philip","sequence":"additional","affiliation":[{"name":"6Clinical Haematology Unit, Department of Medicine, Faculty of Health Sciences, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Smyth","sequence":"additional","affiliation":[{"name":"7Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8430-0120","authenticated-orcid":false,"given":"Dhananjay","family":"Sakrikar","sequence":"additional","affiliation":[{"name":"8Binding Site, Part of Thermo Fisher Scientific, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Perkins","sequence":"additional","affiliation":[{"name":"9Binding Site Group, Part of Thermo Fisher Scientific, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Harding","sequence":"additional","affiliation":[{"name":"9Binding Site Group, Part of Thermo Fisher Scientific, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Troske","sequence":"additional","affiliation":[{"name":"8Binding Site, Part of Thermo Fisher Scientific, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Getz","sequence":"additional","affiliation":[{"name":"3Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA"},{"name":"10Center for Cancer Research, Massachusetts General Hospital, Boston, MA"},{"name":"11Cancer Center and Department of Pathology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth W.","family":"Karlson","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"12Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Trippa","sequence":"additional","affiliation":[{"name":"13Biostatistics, T.H. Chan School of Public Health, Harvard University, Cambridge, MA"},{"name":"14Department of Biostatistics and Computational Biology, Dana-Farber Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9128-3012","authenticated-orcid":false,"given":"Catherine R.","family":"Marinac","sequence":"additional","affiliation":[{"name":"1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3248-4906","authenticated-orcid":false,"given":"Wenlong C.","family":"Chen","sequence":"additional","affiliation":[{"name":"7Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"},{"name":"15Strengthening Oncology Services Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"},{"name":"16National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8616-9672","authenticated-orcid":false,"given":"Maureen","family":"Joffe","sequence":"additional","affiliation":[{"name":"15Strengthening Oncology Services Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[{"name":"1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2025032119415345700_bib1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025032119415345700_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025032119415345700_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of\u00a01027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"1-2","key":"2025032119415345700_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cca.2009.04.024","article-title":"Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect","volume":"406","author":"Shaheen","year":"2009","journal-title":"Clin Chim Acta"},{"issue":"2","key":"2025032119415345700_bib5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5858\/1999-123-0114-SOTFMG","article-title":"Sequence of testing for monoclonal gammopathies serum and urine assays","volume":"123","author":"Kyle","year":"1999","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"2025032119415345700_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"2025032119415345700_bib7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free \u03ba and free \u03bb immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clin Chem"},{"issue":"8","key":"2025032119415345700_bib8","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025032119415345700_bib9","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1373\/49.8.1252","article-title":"Practical considerations for the measurement of free light chains in serum","volume":"49","author":"Tate","year":"2003","journal-title":"Clin Chem"},{"issue":"Pt 6","key":"2025032119415345700_bib10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1258\/000456307782268200","article-title":"Serum free light chains; the need to establish local reference intervals","volume":"44","author":"Pattenden","year":"2007","journal-title":"Ann Clin Biochem"},{"key":"2025032119415345700_bib11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.clinbiochem.2018.06.003","article-title":"Reference intervals and diagnostic ranges for serum free \u03ba and free \u03bb immunoglobulin light chains vary by instrument platform: implications for classification of patient results in a multi-center study","volume":"58","author":"Cotten","year":"2018","journal-title":"Clin Biochem"},{"key":"2025032119415345700_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clinbiochem.2017.05.009","article-title":"Evaluation of the N-latex serum free light chain assay on the Siemens BNII analyzer and agreement with the Binding Site FreeLite assay on the SPAPlus","volume":"51","author":"White-Al Habeeb","year":"2018","journal-title":"Clin Biochem"},{"issue":"1","key":"2025032119415345700_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1515\/cclm-2019-0533","article-title":"Method comparison of four clinically available assays for serum free light chain analysis","volume":"58","author":"Fleming","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"2025032119415345700_bib14","first-page":"489","article-title":"Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis","volume":"50","author":"Hoedemakers","year":"2011","journal-title":"Clin Chem Lab Med"},{"issue":"11","key":"2025032119415345700_bib15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrneph.2009.151","article-title":"Serum free light chain assessment in monoclonal gammopathy and kidney disease","volume":"5","author":"Hutchison","year":"2009","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"2025032119415345700_bib16","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2215\/CJN.02290508","article-title":"Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease","volume":"3","author":"Hutchison","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"2025032119415345700_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"issue":"5","key":"2025032119415345700_bib18","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","article-title":"Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study","volume":"9","author":"El-Khoury","year":"2022","journal-title":"Lancet Haematol"},{"issue":"7","key":"2025032119415345700_bib19","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/bloodadvances.2023010843","article-title":"Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population","volume":"8","author":"Lee","year":"2024","journal-title":"Blood Adv"},{"issue":"19","key":"2025032119415345700_bib20","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2025032119415345700_bib21","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1214234","article-title":"Cystatin C versus creatinine in determining risk based on kidney function","volume":"369","author":"Shlipak","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"7571","key":"2025032119415345700_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"1000 Genomes Project Consortium","year":"2015","journal-title":"Nature"},{"issue":"16","key":"2025032119415345700_bib23","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2025032119415345700_bib24","first-page":"2825","article-title":"Scikit-learn: machine learning in Python.","volume":"12","author":"Pedregosa","year":"2011","journal-title":"J\u00a0Mach Learn Res"},{"key":"2025032119415345700_bib25","unstructured":"Sakrikar\n              D\n            , MarrotN, NorthS, . Multi-site verification of the automated EXENT(R) MALDI-TOF-MS system and immunoglobulin isotypes assay for the identification and quantification of monoclonal immunoglobulins. Paper presented at: AACC Annual Scientific Meeting; 28 September 2021; Atlanta, GA. Accessed 7 October 2021. https:\/\/www.abstractsonline.com\/pp8\/#!\/9313\/presentation\/23."},{"key":"2025032119415345700_bib26","author":"Horowitz","year":"2010","edition":"3rd ed"},{"issue":"9727","key":"2025032119415345700_bib27","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"2025032119415345700_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting racial disparities in multiple myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J"},{"issue":"11","key":"2025032119415345700_bib29","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1136\/jclinpath-2013-201511","article-title":"Verification of serum reference intervals for free light chains in a local South African population","volume":"66","author":"Zemlin","year":"2013","journal-title":"J\u00a0Clin Pathol"},{"issue":"6","key":"2025032119415345700_bib30","first-page":"1411","article-title":"Free light chain assay drift: potential for misdiagnosis?","volume":"5","author":"Murray","year":"2020","journal-title":"J\u00a0Appl Lab Med"},{"issue":"4","key":"2025032119415345700_bib31","first-page":"742","article-title":"Kappa free light chain drift prompts the need for a new upper limit of normal free light chain ratio to avoid an epidemic of kappa light chain monoclonal gammopathy of undermined significance","volume":"8","author":"Rozenova","year":"2023","journal-title":"J\u00a0Appl Lab Med"},{"issue":"2","key":"2025032119415345700_bib32","first-page":"394","article-title":"Serum free light chain and drift: calibrator adjustment needed?","volume":"9","author":"Griffiths","year":"2024","journal-title":"J\u00a0Appl Lab Med"},{"issue":"3","key":"2025032119415345700_bib33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ajcp\/aqad137","article-title":"Data analytics improves the diagnostic accuracy of serum free light chain results for detecting monoclonal gammopathy","volume":"161","author":"Treger","year":"2024","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"2025032119415345700_bib34","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1515\/cclm-2022-0347","article-title":"Serum free light chain analysis: persisting limitations with new kids on the block","volume":"60","author":"Van Hoovels","year":"2022","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"2025032119415345700_bib35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Thorsteinsd\u00f3ttir","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"2025032119415345700_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"10","key":"2025032119415345700_bib37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025032119415345700_bib38","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"9","key":"2025032119415345700_bib39","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"2025032119415345700_bib40","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(14)70001-8","article-title":"Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study","volume":"1","author":"Kyle","year":"2014","journal-title":"Lancet Haematol"},{"issue":"13","key":"2025032119415345700_bib41","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.2023022399","article-title":"Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis","volume":"143","author":"Bomsztyk","year":"2024","journal-title":"Blood"},{"key":"2025032119415345700_bib42","doi-asserted-by":"crossref","first-page":"200365","DOI":"10.5888\/pcd18.200365","article-title":"HbA1c performance in African descent populations in the United States with normal glucose tolerance, prediabetes, or diabetes: a scoping review","volume":"18","author":"Khosla","year":"2021","journal-title":"Prev Chronic Dis"},{"issue":"3","key":"2025032119415345700_bib43","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/bloodadvances.2022007680","article-title":"White blood cell ranges and frequency of neutropenia by Duffy genotype status","volume":"7","author":"Bagheri","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/8\/840\/2355725\/blood_bld-2024-026078-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/8\/840\/2355725\/blood_bld-2024-026078-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T20:24:52Z","timestamp":1742588692000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/8\/840\/526098\/Serum-free-light-chains-in-a-racially-diverse"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,2,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026078","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]}}}